The ulcerative colitis lawsuit wave is picking up steam heading into 2026. Thousands of patients who took UC medications like Xeljanz, Rinvoq, and Humira are filing claims against drug manufacturers. They say these companies hid or downplayed the risk of serious side effects.
If you took a UC drug and suffered blood clots, heart problems, or cancer, you might be owed money. Lawsuits are targeting companies like Pfizer and AbbVie for failing to warn patients about known dangers.
This article covers everything happening in 2026. You will learn which drugs are involved, what settlements look like, who qualifies, and how to file a claim before deadlines pass.
Here is one fact worth knowing: the FDA issued a black box warning for Xeljanz in 2021 after a safety study showed a 33% higher risk of major cardiac events. That warning came years after millions of prescriptions were already written.
What Is the Ulcerative Colitis Lawsuit About in 2026
The ulcerative colitis lawsuit refers to legal claims filed by patients who suffered serious harm from UC medications. These lawsuits accuse drug manufacturers of knowing about dangerous side effects and failing to warn doctors and patients.
The core issue is simple. Companies like Pfizer sold drugs that carried hidden risks. Patients trusted their doctors, who relied on incomplete safety information from the manufacturers.
In 2026, the litigation centers mainly around JAK inhibitor drugs. Xeljanz remains the biggest target, but lawsuits involving Rinvoq and other medications are growing fast.
| Key Detail | 2026 Status |
|---|---|
| Primary Drug Targeted | Xeljanz (tofacitinib) |
| Lead Defendant | Pfizer Inc. |
| MDL Court | Western District of Pennsylvania |
| MDL Case Number | MDL 3024 |
| Number of Pending Cases | 2,000+ estimated |
| Main Legal Theory | Failure to warn |
These are not frivolous claims. The FDA itself confirmed elevated risks of blood clots, heart attacks, and cancer in patients taking these drugs. Pfizer’s own post-marketing safety study, known as the ORAL Surveillance trial, revealed these dangers.
Patients argue they would have chosen safer treatments if the drug companies had been honest from the start.
Ulcerative Colitis Lawsuit Settlement Amounts to Expect
Settlement amounts for ulcerative colitis lawsuits in 2026 could range from $100,000 to over $1 million per case. The exact figure depends on the severity of your injury, which drug you took, and how strong your evidence is.
No global settlement has been finalized as of early 2026. But legal experts are watching the Xeljanz MDL closely for signs of resolution.
Think of it like a car accident case. A fender bender gets less than a rollover crash. The worse your injury, the higher the potential payout.
| Injury Severity | Estimated Settlement Range |
|---|---|
| Blood clots (DVT, PE) | $100,000 to $400,000 |
| Heart attack or stroke | $300,000 to $800,000 |
| Cancer diagnosis | $500,000 to $1,500,000 |
| Death (wrongful death claim) | $750,000 to $2,000,000+ |
These numbers come from comparable pharmaceutical mass torts. Past cases involving drugs like Vioxx and Actos produced settlements in similar ranges.
Individual results vary widely. Cases with strong medical records and clear proof of causation will be worth the most. Weak documentation or pre-existing conditions can bring the number down.
Bellwether trials, which are expected to proceed in 2026, will play a big role in setting the value of these cases.
Who Qualifies for the Ulcerative Colitis Lawsuit
You may qualify for the ulcerative colitis lawsuit if you took a UC medication and then developed a serious medical condition. The key drugs include Xeljanz, Rinvoq, Humira, and Zeposia.
Not every patient who took these drugs has a case. There has to be a connection between the medication and a specific injury.
Here are the basic qualifications:
- You were prescribed a UC medication (especially a JAK inhibitor)
- You took the medication for a meaningful period of time
- You developed one or more serious side effects while on the drug or shortly after stopping
- Your side effects were not disclosed or were minimized by the manufacturer
- You have medical records that document both the prescription and the injury
Side effects that typically qualify include:
- Blood clots (deep vein thrombosis or pulmonary embolism)
- Heart attack
- Stroke
- Cancer (especially lymphoma or lung cancer)
- Serious infections requiring hospitalization
- Death (family members can file wrongful death claims)
The strongest cases involve patients who had no prior history of the condition they developed. If you had no heart problems before taking Xeljanz and then suffered a heart attack, that is a strong signal.
Age matters too. The FDA found that patients over 50 faced the highest risk of serious adverse events from JAK inhibitors.
Key Takeaway: Ulcerative colitis lawsuits in 2026 center around drug manufacturers hiding known risks, with potential settlements ranging from $100,000 to over $1 million depending on injury severity.
Xeljanz Ulcerative Colitis Lawsuit Explained
Xeljanz is the primary drug at the center of the ulcerative colitis lawsuit. Manufactured by Pfizer, Xeljanz (tofacitinib) was approved by the FDA in 2012 for rheumatoid arthritis and later in 2018 for ulcerative colitis.
The problem started with a required post-marketing study. The FDA ordered Pfizer to conduct a safety trial after approval. That study, called ORAL Surveillance, ran from 2014 to 2020.
The results were alarming. Patients taking Xeljanz had significantly higher rates of heart attacks, blood clots, cancer, and death compared to those taking TNF inhibitors like Humira.
Key findings from the ORAL Surveillance trial:
- 33% increase in major adverse cardiovascular events (MACE)
- 48% increase in blood clot risk (venous thromboembolism)
- Higher rates of malignancies, including lymphoma and lung cancer
- Elevated mortality risk, especially in patients over 50
Pfizer allegedly knew about safety signals before the study was complete but continued marketing Xeljanz aggressively. Plaintiffs claim the company prioritized profits over patient safety.
The FDA responded in September 2021 by adding a black box warning to Xeljanz. That is the most serious type of warning the FDA can issue. But for many patients, the damage was already done.
| Xeljanz Timeline | Event |
|---|---|
| November 2012 | FDA approves Xeljanz for rheumatoid arthritis |
| May 2018 | FDA approves Xeljanz for ulcerative colitis |
| February 2019 | FDA issues initial safety alert about blood clots |
| January 2021 | ORAL Surveillance trial results released |
| September 2021 | FDA adds black box warning |
| 2022 onward | Lawsuits begin consolidating into MDL 3024 |
Xeljanz Lawsuit Update for 2026
The Xeljanz lawsuit is entering a make-or-break phase in 2026. Bellwether trials are expected to move forward, and these early cases will shape the entire litigation.
MDL 3024 is housed in the U.S. District Court for the Western District of Pennsylvania. Judge Robert Colville is overseeing the proceedings.
As of early 2026, over 2,000 cases are pending in the MDL. New cases continue to be filed every month.
What to watch in 2026:
- Bellwether trial selections are being finalized
- Discovery has produced internal Pfizer documents that plaintiffs say show the company downplayed risks
- Settlement negotiations could accelerate after the first trial verdicts
- Pfizer has signaled it will fight the cases aggressively, but large verdicts could force a global settlement
The bellwether process works like a test run. A small group of representative cases goes to trial first. If plaintiffs win big verdicts, Pfizer will face enormous pressure to settle the remaining cases. If Pfizer wins, it gains leverage to push for lower settlements or even dismissals.
Legal experts estimate that meaningful settlement talks could begin in mid to late 2026, depending on trial outcomes.
Pfizer has not made any public settlement offers as of this writing. The company maintains that Xeljanz is safe when used according to its updated labeling.
Ulcerative Colitis Medication Lawsuit Overview
The ulcerative colitis medication lawsuit is not limited to one drug. Several UC medications are now the subject of legal claims, each involving different manufacturers and different risks.
Here is a snapshot of the drugs involved in litigation:
| Drug Name | Generic Name | Manufacturer | Drug Class | Primary Lawsuit Allegation |
|---|---|---|---|---|
| Xeljanz | Tofacitinib | Pfizer | JAK inhibitor | Heart attack, blood clots, cancer |
| Rinvoq | Upadacitinib | AbbVie | JAK inhibitor | Cardiovascular events, infections |
| Humira | Adalimumab | AbbVie | TNF inhibitor | Cancer risk, serious infections |
| Zeposia | Ozanimod | Bristol Myers Squibb | S1P receptor modulator | Cardiac effects, liver damage |
The lawsuits share a common thread. In each case, plaintiffs say the manufacturer knew about serious risks and either failed to disclose them or actively minimized the dangers in marketing materials.
JAK inhibitors carry the most litigation activity right now. The FDA’s class-wide warning in 2021, which applied to all JAK inhibitors, gave plaintiffs a powerful piece of evidence.
But TNF inhibitors like Humira face their own set of claims. Some patients developed rare cancers, including hepatosplenic T-cell lymphoma, after taking these drugs.
The legal theories are similar across all cases: product liability, failure to warn, and negligent misrepresentation.
Key Takeaway: Xeljanz dominates the 2026 UC litigation, but Rinvoq, Humira, and Zeposia are all facing legal challenges, and bellwether trials could trigger massive settlement negotiations.
Ulcerative Colitis Lawsuit Payout Breakdown
Ulcerative colitis lawsuit payouts will depend on a tier system once settlements are reached. Pharmaceutical mass torts almost always use tiered structures to sort cases by injury severity.
The most common approach divides plaintiffs into categories. Each tier gets a different payout range based on the seriousness of the harm.
Typical payout tier structure:
| Tier | Injury Type | Expected Payout Range |
|---|---|---|
| Tier 1 (Highest) | Death, cancer, major cardiac event with lasting disability | $500,000 to $2,000,000+ |
| Tier 2 (High) | Heart attack, stroke, or pulmonary embolism with recovery | $200,000 to $600,000 |
| Tier 3 (Moderate) | Deep vein thrombosis, serious infection requiring hospitalization | $100,000 to $300,000 |
| Tier 4 (Lower) | Minor clotting events, less severe adverse reactions | $25,000 to $100,000 |
Attorney fees typically run between 33% and 40% of the settlement amount. That comes off the top before you receive your share.
Some cases may be worth significantly more if they go to individual trial rather than settling as part of a group. Trial verdicts in pharmaceutical cases have occasionally reached eight figures.
Keep in mind, no settlement fund has been established yet as of early 2026. These projections are based on legal analysis and comparisons with similar drug litigation outcomes from the past decade.
Your actual payout also depends on factors like how long you took the drug, whether you needed surgery, and the total medical costs you incurred.
How to File an Ulcerative Colitis Lawsuit
Filing an ulcerative colitis lawsuit starts with contacting a lawyer who handles pharmaceutical mass torts. You don’t pay anything upfront because these cases work on a contingency fee basis.
Here is the step-by-step process:
- Contact a mass tort attorney who specializes in pharmaceutical cases
- Complete a case evaluation where the lawyer reviews your medical history and drug use
- Sign a retainer agreement if the attorney determines you have a viable claim
- Gather medical records showing your prescription history and the injury you suffered
- Your case is filed in the appropriate court, usually as part of the MDL
- Discovery and litigation proceed, during which your attorney builds your case
- Settlement or trial produces your payout
The entire process from filing to resolution can take 1 to 4 years. Mass tort cases are slow. They involve thousands of plaintiffs and enormous amounts of evidence.
You won’t need to appear in court for most of the process. Your attorney handles nearly everything. You may need to provide a deposition at some point, which is a recorded interview about your experience with the drug.
Quick Facts:
- No upfront cost to file
- Attorney fees: typically 33% to 40% of any recovery
- You keep all rights to your claim throughout
- Filing does not require you to appear in court personally
Rinvoq Lawsuit and Ulcerative Colitis Claims
Rinvoq (upadacitinib) is a JAK inhibitor manufactured by AbbVie. It received FDA approval for ulcerative colitis in March 2022 and has since become a growing target for legal claims.
Like Xeljanz, Rinvoq carries an FDA black box warning for serious risks. These include major cardiovascular events, blood clots, cancer, and death.
The FDA’s 2021 class-wide decision applied to all JAK inhibitors, not just Xeljanz. That means Rinvoq and other JAK inhibitors in the same drug class now carry identical warnings.
Rinvoq risk profile:
- Increased risk of major adverse cardiovascular events
- Higher incidence of venous thromboembolism
- Elevated cancer risk, particularly lymphoma
- Serious and sometimes fatal infections
- Gastrointestinal perforations
Rinvoq lawsuits are still in earlier stages compared to Xeljanz cases. But the legal framework is nearly identical. Plaintiffs allege that AbbVie failed to adequately warn about these risks.
| Rinvoq Detail | Info |
|---|---|
| Manufacturer | AbbVie |
| FDA UC Approval | March 2022 |
| Drug Class | JAK inhibitor |
| Black Box Warning | Yes (class-wide, 2021) |
| Current Lawsuit Status | Individual filings growing; no MDL yet |
AbbVie faces a unique challenge. The company also makes Humira, so it is defending lawsuits on two UC drugs at the same time. That dual exposure could affect its willingness to settle.
Patients who took Rinvoq and suffered cardiac events, blood clots, or cancer should talk to a lawyer now. The earlier you file, the stronger your position tends to be.
Key Takeaway: Rinvoq lawsuits are growing fast in 2026, and the FDA’s class-wide black box warning on all JAK inhibitors gives plaintiffs strong evidence for their claims.
JAK Inhibitor Lawsuit Developments in 2026
JAK inhibitor lawsuits represent the largest category within UC drug litigation. These drugs, which include Xeljanz, Rinvoq, and Olumiant, work by blocking Janus kinase enzymes in the immune system.
The FDA’s landmark 2021 safety communication changed everything. After reviewing the ORAL Surveillance trial results, the agency required all JAK inhibitors to carry black box warnings for cardiovascular events, blood clots, cancer, and death.
That regulatory action is the backbone of nearly every JAK inhibitor lawsuit. Plaintiffs point to the FDA’s findings as proof that these drugs are more dangerous than manufacturers led patients and doctors to believe.
2026 JAK inhibitor litigation milestones to watch:
- Xeljanz bellwether trials in MDL 3024
- Potential consolidation of Rinvoq cases into a new MDL
- Growing plaintiff pool as more patients learn about their legal rights
- Internal company documents from discovery that may reveal what manufacturers knew and when
The class-wide nature of the FDA’s warning helps plaintiffs across all JAK inhibitor cases. It is hard for any manufacturer to argue its specific JAK inhibitor is safe when the FDA has said the entire drug class poses elevated risks.
One thing to watch: newer JAK inhibitors like deucravacitinib (Sotyktu) are designed to be more selective. Whether they carry the same risks remains to be seen, and they could eventually face their own litigation if safety problems emerge.
For now, Xeljanz and Rinvoq are the primary targets. Together, they account for the overwhelming majority of JAK inhibitor UC lawsuits filed as of 2026.
Ulcerative Colitis Drug Side Effects Behind the Lawsuits
The side effects driving these lawsuits are not minor complaints. We are talking about life-threatening conditions that permanently changed people’s lives or killed them.
Here is what patients experienced:
Cardiovascular events:
- Heart attacks, including fatal ones
- Strokes leading to permanent disability
- Major adverse cardiovascular events (MACE)
Blood clots:
- Deep vein thrombosis (DVT), typically in the legs
- Pulmonary embolism (PE), a clot that travels to the lungs
- Both conditions can be fatal if not treated immediately
Cancer:
- Lymphoma, including rare and aggressive forms
- Lung cancer
- Other malignancies linked to immune system suppression
Serious infections:
- Tuberculosis reactivation
- Opportunistic fungal infections
- Bacterial infections requiring hospitalization
Other complications:
- Gastrointestinal perforations (a hole in the stomach or intestine)
- Liver damage
- Death
| Side Effect | Reported Increase Over Comparator |
|---|---|
| MACE | 33% higher with Xeljanz |
| Blood clots (VTE) | 48% higher with Xeljanz |
| Malignancies | Significantly elevated across JAK inhibitors |
| All-cause mortality | Higher in patients over 50 |
The reason these side effects matter legally is that manufacturers allegedly knew about many of these risks before patients did. Internal safety data, early clinical trial signals, and post-marketing reports all pointed to trouble. But the warnings were slow to arrive.
Is There an Ulcerative Colitis Class Action Lawsuit
There is no class action lawsuit for ulcerative colitis medications in 2026. Instead, these cases are handled as a mass tort through multidistrict litigation (MDL).
The difference matters. In a class action, one outcome applies to everyone. In a mass tort, each person’s case is evaluated individually. You get your own settlement based on your own injuries.
Think of it this way: a class action is like everyone getting the same size slice of pie. A mass tort means your slice depends on how badly you were hurt.
Class Action vs. Mass Tort:
| Feature | Class Action | Mass Tort (MDL) |
|---|---|---|
| Individual case evaluation | No | Yes |
| Settlement based on personal injury | No | Yes |
| One verdict applies to all | Yes | No |
| Cases consolidated for efficiency | Yes | Yes |
| You need your own attorney | Sometimes | Yes |
The Xeljanz MDL (MDL 3024) is the primary consolidation vehicle right now. Cases from across the country are transferred to the Western District of Pennsylvania for coordinated pretrial proceedings.
Individual cases can still go to trial separately. And if a global settlement is reached, each plaintiff’s payout will be calculated based on their specific circumstances.
If you hear someone call this a “class action,” they are using the term loosely. Technically, it is mass tort litigation.
Humira Ulcerative Colitis Lawsuit Status
Humira (adalimumab), made by AbbVie, is one of the best-selling drugs in pharmaceutical history. It has generated over $200 billion in lifetime sales. It is also facing lawsuits from UC patients.
The Humira lawsuits focus on a different set of side effects than the JAK inhibitor cases. Plaintiffs allege that AbbVie failed to warn about the risk of rare cancers and serious infections.
Specific Humira allegations:
- Increased risk of lymphoma, including hepatosplenic T-cell lymphoma (a rare and often fatal cancer)
- Higher rates of serious infections, including tuberculosis and invasive fungal infections
- Failure to adequately communicate risks to prescribing physicians
- Marketing that emphasized benefits while downplaying safety concerns
| Humira Detail | Info |
|---|---|
| Manufacturer | AbbVie |
| Drug Class | TNF inhibitor |
| FDA Approval for UC | September 2012 |
| Black Box Warning | Yes (for infections and malignancies) |
| Lawsuit Status | Individual filings; no dedicated MDL |
Humira lawsuits are not as far along as the Xeljanz litigation. There is no dedicated MDL for Humira UC claims as of early 2026. Cases are being filed in various state and federal courts.
But the sheer number of patients who took Humira for UC makes this a significant area of litigation. AbbVie’s aggressive direct-to-consumer advertising is expected to be a major focus at trial.
The company spent billions promoting Humira. Plaintiffs argue that marketing created a false sense of safety among patients and doctors alike.
Key Takeaway: There is no class action for UC drug lawsuits; cases are handled individually through mass tort MDL proceedings, and Humira litigation is building alongside the larger Xeljanz MDL.
Ulcerative Colitis Medication Side Effects Claims
Ulcerative colitis medication side effects claims are legal actions based on harm caused by specific drugs. These claims require proof that the drug caused an injury the manufacturer should have warned about.
The legal standard is straightforward. You need to show three things:
- You took the medication
- You suffered a specific injury
- The injury was caused by the medication, and the manufacturer failed to warn you
Types of claims being filed:
- Product liability: The drug was unreasonably dangerous
- Failure to warn: The manufacturer didn’t adequately inform patients or doctors about risks
- Negligence: The manufacturer failed to exercise reasonable care in testing, marketing, or monitoring the drug
- Fraudulent concealment: The manufacturer actively hid known risks
- Breach of warranty: The drug did not perform as promised
Most UC medication claims fall under failure to warn. This is the most common legal theory in pharmaceutical lawsuits because it puts the spotlight on what the company knew and when it knew it.
What makes a strong claim:
- Clear prescription records showing you took the drug
- Medical records documenting the onset of your injury during or after drug use
- No pre-existing history of the condition that developed
- Evidence that the manufacturer knew about the risk before your injury
- A timeline showing the injury occurred within a plausible window of drug exposure
Your attorney will work with medical experts to establish causation. This is often the most contested part of the case.
Ulcerative Colitis Lawsuit Deadline in 2026
The deadline to file an ulcerative colitis lawsuit depends on your state’s statute of limitations. Most states give you 2 to 6 years from the date you discovered (or should have discovered) the injury.
This is critical. If you miss the deadline, you lose your right to file. Forever. No exceptions in most jurisdictions.
Statute of limitations by state (selected examples):
| State | Statute of Limitations (Personal Injury) |
|---|---|
| California | 2 years |
| Texas | 2 years |
| New York | 3 years |
| Florida | 4 years |
| Illinois | 2 years |
| Pennsylvania | 2 years |
| Ohio | 2 years |
| Michigan | 3 years |
The clock usually starts ticking from the “discovery date.” That is when you first knew, or reasonably should have known, that the drug caused your injury. For many patients, this date corresponds with the FDA’s 2021 black box warning or when their doctor informed them of the connection.
Key deadline factors:
- The discovery rule can extend your filing window beyond the standard statute of limitations
- Minors may have extended deadlines
- Wrongful death claims may have different timelines
- Some states have special rules for pharmaceutical cases
Do not wait until 2027 to act. If you believe you were harmed by a UC medication, talk to a lawyer now. Even if you are unsure about the deadline, a quick consultation can clarify your situation.
Evidence Needed for an Ulcerative Colitis Lawsuit
The evidence needed for an ulcerative colitis lawsuit includes medical records, prescription history, and documentation of your injury. Strong evidence separates cases worth six figures from those that go nowhere.
Essential evidence checklist:
- Prescription records: Pharmacy printouts showing the drug name, dosage, dates filled, and prescribing doctor
- Medical records: Hospital records, doctor visit notes, lab results, and imaging studies that document your injury
- Diagnosis records: Official diagnosis of the side effect (blood clot, heart attack, cancer, etc.)
- Timeline documentation: Records showing when you started the drug, when symptoms appeared, and when you were diagnosed
- Treatment records: Proof of surgeries, hospitalizations, rehabilitation, or ongoing care related to the injury
Helpful but not always required:
- Insurance claims and billing records
- Employment records showing lost wages
- Personal journal or notes documenting symptoms
- Statements from family members about how the injury affected your daily life
- Before-and-after medical records proving no pre-existing condition
| Evidence Type | Why It Matters |
|---|---|
| Prescription records | Proves you took the drug |
| Medical records of injury | Proves you were harmed |
| Timeline documentation | Shows connection between drug and injury |
| Pre-existing condition records | Rules out other causes |
| Treatment and billing records | Establishes damages (your financial losses) |
Start gathering this evidence as soon as possible. Medical records can be harder to obtain as time passes. Pharmacies may purge old prescription data.
Your attorney’s legal team will help you collect and organize everything. But the more you can provide early on, the faster and stronger your case will be.
Key Takeaway: Gathering prescription records, medical documentation, and a clear injury timeline early gives your case the best chance at a high payout.
Choosing an Ulcerative Colitis Lawsuit Lawyer
The right ulcerative colitis lawsuit lawyer can make or break your case. You want someone with specific experience in pharmaceutical mass torts, not a general practice attorney.
What to look for in a UC lawsuit attorney:
- Mass tort experience: They should have handled large-scale pharmaceutical cases before
- Contingency fee structure: You pay nothing unless they win your case
- Resources: Mass torts require significant investment in medical experts, document review, and litigation staff
- Track record: Ask about past pharmaceutical settlements and verdicts they have achieved
- Communication: They should keep you updated and be available to answer questions
Red flags to avoid:
- Attorneys who guarantee a specific dollar amount before reviewing your case
- Firms that pressure you to sign immediately
- Lawyers with no pharmaceutical litigation history
- Any firm asking for upfront fees
| Question to Ask | Why It Matters |
|---|---|
| How many pharmaceutical cases have you handled? | Shows relevant experience |
| What is your fee structure? | Should be contingency only |
| Will you handle my case or refer it? | Some firms collect cases and pass them to other attorneys |
| What is the expected timeline? | Sets realistic expectations |
| How will you communicate updates? | Ensures you stay informed |
A good lawyer will offer a free case evaluation. During this initial review, they will assess whether you have a viable claim.
Do not pick the first firm you find online. Compare at least 2 to 3 attorneys. Look for reviews from real clients who had pharmaceutical cases, not just generic testimonials.
Your attorney is your partner in this process. Choose someone you trust and who has the firepower to take on billion-dollar drug companies.
Frequently Asked Questions
How much money can I get from an ulcerative colitis lawsuit in 2026?
Most settlements are expected to range from $100,000 to over $1 million, depending on injury severity.
Cases involving death, cancer, or major cardiac events typically receive the highest payouts.
No global settlement has been finalized yet as of early 2026.
What medications are involved in ulcerative colitis lawsuits?
The primary drugs are Xeljanz, Rinvoq, Humira, and Zeposia.
JAK inhibitors like Xeljanz and Rinvoq face the most litigation due to the FDA’s class-wide black box warning.
TNF inhibitors like Humira are also being targeted for cancer and infection risks.
Is there a deadline to file an ulcerative colitis lawsuit?
Yes, every state has a statute of limitations, typically 2 to 6 years from the date of discovery.
The discovery date is when you first knew or should have known the drug caused your injury.
Missing this deadline means you permanently lose the right to file.
Do I need a lawyer to file an ulcerative colitis lawsuit?
You technically can file alone, but it is strongly recommended to hire a mass tort attorney.
These cases involve complex medical evidence and large corporate legal teams.
Most UC lawsuit lawyers work on contingency, meaning you pay nothing unless you win.
What side effects qualify me for an ulcerative colitis drug lawsuit?
Qualifying side effects include blood clots, heart attacks, strokes, cancer, serious infections, and death.
These conditions must have developed during or shortly after taking the medication.
Cases are strongest when there is no prior history of the condition.
If you took a UC medication and suffered a serious health problem, 2026 is the year to act. Bellwether trials are approaching, and settlement talks could follow soon after.
Start by gathering your medical records and prescription history. Then reach out to a mass tort attorney for a free case review.
The window to file is open right now. Don’t let it close on you.
